Sun Pharmaceutical has launched its semaglutide injection under the brand names Noveltreat and Sematrinity in India, in all strengths.

Noveltreat is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet & increased physical activity and is available in five dose strengths – 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and2.4 mg/0.75 mL.

Sematrinity is indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, and is available in two dose strengths – 2 mg/1.5 mL and 4 mg/3 mL.

Priced significantly below the innovator brand, the weekly therapy cost ranges from approximately INR 900 to INR 2,000 for Noveltreat and INR 750 to INR 1,300 for Sematrinity.

Commenting on the launch, Kirti Ganorkar, Managing Director (MD), Sun Pharmaceutical, said, “With the launch of Noveltreat and Sematrinity, our endeavour is to provide a high-quality, affordable therapy to a wider patient community in India. We are offering a comprehensive range, backed by our decades of expertise in manufacturing complex medicines. To further support patients, we are also introducing a holistic patient support programme intended to guide them throughout their treatment journey”.

Noveltreat’s pre-filled pen uses a concealed needle to help ease injection fear and improve both handling safety and dosing accuracy. Sematrinity comes in a multi-dose pen format that offers flexible dosing, with a smooth dialer that enables accurate dose delivery.